B Group, Inc.
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), B Group, Inc. reported 15 stock positions worth $134.9 million. Its top holding was Adma Biologics (ADMA) at 33.2% of the portfolio, followed by Cellectis - ADR (CLLS, 11.8%) and Palisade Bio (PALI, 7.8%). Compared with Q3 2025, it opened 2 new positions, sold out of 3, added to 2 and reduced 2. The biggest buy was a new position in Palisade Bio (PALI) and the biggest sale an exit from Akero Therapeutics (AKRO).
- Most Recent 13F
- Q2 2026
- Location
- DALLAS, TX
- CIK
- 0002043476
- Portfolio Value
- $134.9M (Q4 2025)
- SEC Filing
- 0001420506-26-000462 ↗ filed Feb 17, 2026
Holdings Value
Holdings 15 stocks · $134.9M
| ADMA Adma Biologics Inc. | 33.22% | 2,457,542 | $44.8M | Add +1.9% |
| CLLS Cellectis - ADR | 11.77% | 3,281,501 | $15.9M | No change |
| PALI Palisade Bio Inc. | 7.84% | 4,500,000 | $10.6M | New |
| TSHA Taysha Gene Therapies Inc. | 7.34% | 1,800,556 | $9.9M | No change |
| PRAX Praxis Precision Medicines I | 7.26% | 33,237 | $9.8M | Add +5.5% |
| SGHT Sight Sciences Inc. | 5.41% | 920,000 | $7.3M | Reduce -1.1% |
| ZLAB Zai Lab Ltd.-ADR | 5.23% | 400,000 | $7.1M | No change |
| GPCR Structure Therapeutics Inc. | 4.64% | 90,000 | $6.3M | New |
| ASMB Assembly Biosciences Inc. | 4.43% | 175,706 | $6.0M | No change |
| IOVA Iovance Biotherapeutics Inc. | 3.03% | 1,500,000 | $4.1M | No change |
| SYRE Spyre Therapeutics Inc. | 2.43% | 100,000 | $3.3M | No change |
| AURA Aura Biosciences Inc. | 2.31% | 572,576 | $3.1M | No change |
| RARE Ultragenyx Pharmaceutical Inc. | 2.30% | 135,000 | $3.1M | No change |
| ORKA Oruka Therapeutics Inc. | 1.68% | 75,000 | $2.3M | No change |
| APGE Apogee Therapeutics Inc. | 1.12% | 20,000 | $1.5M | Reduce -42.9% |
Options reported separately and not counted above: REPL calls ($486K).
Portfolio Sells Q3 2025 → Q4 2025
Portfolio Buys Q3 2025 → Q4 2025
Options Activity Q3 2025 → Q4 2025
| LLY Eli Lilly & Co. | put | Sold out | 22,500 | $17.2Mbefore exit |
| NVDA Nvidia Corp. | put | Sold out | 75,000 | $14.0Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q3 2025 → Q4 2025
| NRXPW NRX Pharmaceuticals Inc.-CW22 | *W EXP 05/24/202 | Sold out | 3,000,000 | $4.5Mbefore exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 18 | $176.2M | ADMA, PALI, NRXP, FTH, TSHA |
| Q1 2026 | 20 | $134.9M | ADMA, PALI, PRAX, CLLS, ZLAB |
| Q4 2025 | 15 | $134.9M | ADMA, CLLS, PALI, TSHA, PRAX |
| Q3 2025 | 16 | $100.1M | ADMA, ZLAB, AKRO, CLLS, TSHA |
| Q2 2025 | 15 | $115.8M | ADMA, INSM, ZLAB, AKRO, CLLS |
| Q1 2025 | 17 | $115.1M | ADMA, INSM, ZLAB, AKRO, IOVA |
| Q4 2024 | 18 | $163.6M | INVESCO QQQ TR, ADMA, INSM, ZLAB, IOVA |